The Fritsma Factor
Clumsy Clinical Communication Let's Blame The Lab
What must all Medical Laboratory Scientists Know About Diagnostic Errors? George A. Fritsma MS, MLS The Fritsma Fador, Your Interactive Hemostasis Resource george@fifismafador.com-fiftsmafador.com
PROUDEY SUPPORTED BY PrecisionBioLogic



The Fritsma Factor

The Cindy Johns Scholarship

A champion of the medical laboratory profession, ASCP board member, and ASCP patient champion, *Cynthia Johns, MSA, MASCP, MLS (ASCP)^{CM} SH^{CM}*, passed away December 24, 2017. In honor of Cindy's contributions, the ASCP Foundation supports an endowment to promote the future of the profession through scholarships. Your gift will allow the Foundation to provide scholarships to laboratory students across the country.

PROUDLY SUPPORTED BY PrecisionBioLogic

3



The Fritsma Factor

Bottom Line at the Start [BLAST]

The participant...

5

2

- · Explores indication-based diagnostic test orders.
- Lists test utilization errors.
- Improves communication among lab personnel, providers, and patients.
- Manages blood specimens.
- Applies advanced communication approaches.



george@fritsmafactor.com









10

george@fritsmafactor.com











17













PROUDLY SUPPORTED BY PrecisionBioLogic



The Fritsma Factor

Communication Barriers and Solutions



26



27



















First word or term	Use specific analyte or panel name or its ubiquitous abbreviation (eg. WBC)
Analyte and panel names	Spell out completely if possible
	Must be ubiquitously understood, even if abbreviated
	Full name may be followed by equivalent and more commonly used abbreviation enclosed in parentheses
Analytes with conjugated forms	Use the full name, not conjugated form
Necessary components	Include all necessary components for correct interpretation (does not apply to panels)
Medication (drug) levels	Put "level" after the name of the analyte (eg, Vancomycin Level)
Antibody tests	Do not prefix with "anti"
	Include specific antibody (eg, IgG, IgM) just after the analyte name, or use "antibody" or "Ab" for total antibody tests
Panels	Specify components analyzed when ≤3 and when sufficient character space
Special characters	Do not use forward slashes to represent "and" except for "w/" for "with/" and "w/o" for "without." Forward slashes can be confused with ratios, "divided by," etc
	Do not use single apostrophe ('), asterisk (*), the at symbol (0), pound sign (#), less-than sign (<) or greater-than sign (>), as they may perform unanticipated functions in information systems
Specimen types	Do not include specimen type in the name if the specimen type is peripheral blood, a peripheral blood derivative (eg. serum, plasma) or a test performed on multiple specimers (eg, tissue culture) unless necessary to differentiate from a similarly named test
	For all other tests performed on single specimen types, add the specimen type after the test name
Condition or time	If the test should only be used for a specific condition or time, add it after the analyte name (eg. fasting, peak)
Reflex tests	Add the word "reflex" after the analyte name to indicate to the ordering clinician that the test includes a reflex test. Identify included reflex test name(s) if sufficient space available
Superfluous information	Do not include information that is unnecessary for the ordering provider to know (eg, do not include test method if there is only one method available for this analyte)





The Fritsma Factor	
2021 Round Table, Denve	er, CO; Specimen integrity
Collectors never see the lab, out all day Turnover: improve collector pay, give recognition, require certification Tube specimens to lab [not PFts] Infusion set "butterfly" increases short draws, hemolysis, clotting o Dernis Ernst: butterfly 5X expense, 5X accidental sloks Small hospital, ER docs on locum, weekly changes, order variance	Line draws associated with hemolysis Or PVO design meant o allwish hemolysis Small volume [ped] tubes: poor vacuum, short draws, colume of blood, if not, re- sticks and add-on orders Unnecessary daily orders Ghost patient orders, died or gone home Patients with name changes Naming newborns, unnamed patients
PROUDLY SUPPORTED	^{1 Br} PrecisionBioLogic 40

















Back to the Choosing Wisely Recommendation Do not order daily blood from inpatients without indications. *Think twice, stick once.*" Patient fragility, exsanguination, latrogenic anemia, anemia of chronic inflammation Many assays don't change overight A1C, lipid panels, throid, serology assays Patient experience scores affect Medicare payments. Most daily collections produce unused information. 2.1 per patient per day; "think twice, stick once" Costs to facility, charges to patient

^{BY} Precision*BioLogi*

PROUDLY SUPPORT

50



	Litample. In		JIIE
Assay	Patient	RI	 Triple heterozygot
Protein C activity	35%	>70%	Increase Coumad Stort honorin?
Protein S activity	39%	>65%	Consult with the la
Antithrombin activity	57%	78-126%	
Factor VIII	125%	50-186%	and the second sec
APCR	2.4	>1.8	AL CARDONNESS
Factor II 20210	Wild-type	Wild-type	
PTT-LA	39 s	30–40 s	and the second
Homocysteine	3.9 ηmol/L	<4.3 ηmol/L	
60-YO man, DVT; warfarin	3 W		
	PROLIDIY SU	PORTED RY P	

Th YOUR IN	e Fritsma F eractive hemostasis resource Thro	actor mbophil	ia Profile	Narrative Report
	Assay	Patient	RI	
	Protein C activity	35%	>70%	Or: "Protein C, S, and AT appear
	Protein S activity	39%	>65%	deficient, probably warrarin
	Antithrombin activity	57%	78-126%	Interierence, reliex INR = 2.1, suggesting warfarin is present. Other
	Factor VIII	125%	50-186%	rick factor assau results are within
	APCR	2.4	>1.8	reference interval. No evidence for
	Factor II 20210	Wild-type	Wild-type	thrombotic risk repeat profile 2 weeks
	PTT-LA	39 s	30–40 s	after discontinuing warfarin."
	Homocysteine	3.9 ηmol/L	<4.3 ηmol/L	· · · · · · · · · · · · · · · · · · ·
		Р	ROUDLY SUPPORTED BY PA	szcisionBioLogic 53

The Fritsma Factor Pre-op Screen: Isolated Prolonged PTT Heparin present?Risk: bleeding? Thrombosis?Repeat PTT until negative? Assay Patient 14.2 g/dL 13.5-15.6 g/dL HGB PTT 59 s 25-35 s Consult with laboratory? PT 12.4 s 9.8-12.6 s · Laboratory immediate reflex to. Π 18.2 s <21 s PLT count 310,000/µL 250-450,000/µL Fibrinogen 270 mg/dL 150-400 mg/dL to bleeding Hx, surgeon postpones PROUDLY SUPPORTED BY Previ





The YOUR INTER	The Fritsma Factor				
LA Profile: Third Day of Hospital Stay					
	Assay	Result	RI	Comment	
	PTT-LA	47.9 s	30-40 s	Confirms PTT	
	PTT-LA /control 1:1	38.5 s	Control 34.5 s	Possible LA	
	Staclot LA kit	12 s	> 8 s correction	Confirms LA	
	DRVVT	52.5 s	35–45 s	Possible LA	
	DRVVT confirm	1.4 ratio	> 1.2 correction	Confirms LA	
	Send this result to the surgeon w/o comment? Delay surgery? Consult with laboratory?				
	ARE SICK	PROLID	Y SUPPORTED BY PrecisionBioLog	ic .	

Assay	Result	RI	Comment
PTT-LA	47.9 s	30-40 s	Confirms PTT
PTT-LA /control 1:1	38.5 s	Control 34.5 s	Possible LA
Staclot LA kit	12 s	> 8s correction	Confirms LA
DRVVT	52.5 s	35–45 s	Possible LA
DRVVT confirm	1.4 ratio	> 1.2 correction	Confirms LA
ient plasma tested us longed, both correct g risk, may indicate th nce."	sing LA-sensitive P ed by high phospho prombosis risk if LA PROLOUY SUPPORT	TT reagent and dilute blipid neutralization re l is chronic. Repeat af	Russell viper veno agent, confirming L ter 12 weeks to det



The Fritsma Factor

Assistive Algorithm [2013]

- IOM says, "facilitate more effective teamwork in the diagnostic process among health care professionals, patients, and their families"
- Provider selects or enters indications gathered from patient Hx and physical.
- Algorithm returns recommendations for imaging, tests and test profiles

PrecisionBioLogi

Provider makes choices.

61

The Fritsma Factor

Indication-based Laboratory Utilization [2016]

- · Team of clinical and technical practitioners establishes algorithms
- · Hemostasis indication examples
- Current complaint—chest pain, shortness of breath, bruising, swollen leg
 History of prior events, first-degree relatives
- Age, sex, BMI, race, habits
- List applicable hemostasis assays: D-D, PT, PTT, TT, FG, PC, PS, factor assay, PLT count, PLT aggregometry
- List hemostasis assay profiles: thrombophilia, anatomic bleeding, systemic bleeding, arterial thrombosis
- Match selected lists of indications with hemostasis laboratory assays and profiles.

PROUDLY SUPPORTED BY PrecisionBioLogic

62

The Fritsma Factor

Web-based Narrative Reports [2014]

- Reporting system with 119 coagulation & 38 viscoelastometry [VET] synoptic templates.
- Enter up to 29 coag findings: PT, PTT, TT, PLT count and aggs, VWD profile, LA profile, more
- + Enter VET findings: R, $\alpha,$ MA, Ly30, shake and bake
- "Baseline PTT is prolonged, corrected with mix, TT is normal. Impression: results intrinsic pathway factor deficiency: VIII, IX, XI, XII, VWF. CPT 85390."

63

The Fritsma Factor

- Diagnostic Management Team Accomplishments
- Emerging molecular assays pinpoint diagnosis.
- Molecular pharmacogenomics pinpoint effective treatment.
- DMTs successfully implemented in coagulation, leukemia and lymphoma, transfusion medicine, microbiology/infectious disease, and child abuse.
- · Assembly of disorder-based DMTs with access to lab and imaging data
- Remote systems allow for direct contact among specialties and with PCP and patient.
- Shortens inpatient stay for coagulation disorders from ~4 days to ~2.
- Reduces readmissions for relapse or missed diagnosis.
- Accurate treatment begins at an earlier stage.

Verna R, Velazquez AB, Laposata M. Reducing diagnostic errors worldwide through diagnostic management teams. Ann Lab Med. 2019 ;39:121–4. doi: 10.3343/alm.2019.39.2.121.



The Fritsma Factor your interactive hemostasis resource

Pathology Explanation Clinics

Providers from a tertiary care center were asked, "How interested would you be in having your patient see a pathologist to discuss their path report and see their tissue image?"

Providers ranked their interest, then expanded on concerns and benefits. Of 35 providers interviewed, 83% suggest that highly educated and motivated patients could benefit from a PEC.

PECs could improve understanding and emotional processing, but information must be balanced with the potential for cognitive overload and emotional distress. Providers worried about the pathologist's communication skills, care fragmentation, and

Increased clinician workload. If performed well, providers felt PECs could raise efficacy and improve quality of care.

Bergholtz SE, et al, A mixed-methods study of clinicians' attitudes toward pathology explanation clinics, AJCP 2023;159, 437447, https://doi.org/10.1093/ajcp/aqac175 Processorg/clinicians' attitudes toward pathology explanation clinics, AJCP 2023;159, 437447, PROCESSING STREET, PROCESSING STREET







Quesada AE, Jabbuga CE, Nguyen A, et al. Interpretation of coagulation test results using a web-based reporting system. Lab Medicine 2014/45/343-56.















The Fritsma Factor

Machine Learning of

Cognitive/Functional Decline Markers For cognitive and functional decline, the most important determinants were platelet court, platelet-leukocyte ratio, neutrophil-leukocyte ratio, hemoglobin, RDW, hematocrit, enythrocyte count, essionphil count, maosophil count, monocyte count, globulin, cortisol, glucose, B12, creatinine, GGT, ALT, AST, triglycerides, and HDLc. Cognitive decline accuracy=0.79, functional decline accuracy=0.92. Routine laboratory variables could be applied to predict cognitive and functional decline in populations ≥75 YOA using ML algorithms.

Gomes KB, Pereira RG, Braga AA, et al... Machine learning-based routine laboratory tests predict one-year cognitive and functional decline in a population aged 75+ years. Brain Sci 2023;13. https://doi.org/10.3390/brainscl13040680 PROCESSFACTIONED PredicateSciefe 77

73

The Fritsma Factor

AI/ML-Based Software as a Medical Device Action Plan

- Further develop the proposed regulatory framework, including through issuance of draft guidance on a predetermined change control plan (for software's learning over time);
- Support the development of good machine learning practices to evaluate and improve
- machine learning algorithms;
- Foster a patient-centered approach, including device transparency to users;
- Develop methods to evaluate and improve machine learning algorithms; and
 Advance real-world performance monitoring pilots.

Digital Health Software Precertification (Pre-Cert) Pilot Program FDA 2022 PROUDLY SUPPORTED BY Precision8ioLogic

74

The Fritsma Factor

Bottom Line at the End [BLEAT]

The participant...

- · Explores indication-based diagnostic test orders.
- Lists test utilization errors.
- · Improves communication among lab personnel, providers, and patients.

PROUDLY SUPPORTED BY PrecisionBioLogic

- · Manages blood specimens.
- Applies advanced communication approaches.

75